skip to content »

Department of Neurology

Houston, Texas

BCM neurologists see patients through the Baylor Clinic and some of the world's leading specialty clinics.
Department of Neurology
not shown on screen

Rachelle S. Doody, M.D., Ph.D.

Rachelle S. Doody

Professor of Neurology
Effie Marie Cain Chair in Alzheimer's Disease Research

 

Clinical Service Area

Neurology

Specialty

Alzheimer's Disease
Memory Disorders

Board Certification

American Board of Psychiatry and Neurology, Neurology

Clinic Appointments

713-798-4734

Consult

713-798-4734

Medical School

Baylor College of Medicine, Houston, TX

Internship

Internal Medicine, McGill University Faculty of Medicine, Montreal, Quebec , Canada

Residency

Neurology, Baylor College of Medicine, Houston, TX

Clinical Interests

Alzheimer's disease, neurodegenerative dementias, Ischernic Vascular Dementia, memory loss, mild cognitive impairment

Clinic Location

      Baylor Neurology
      Smith Tower

      6550 Fannin St., Suite 1801
      Houston, TX 77030

Research Interests

Cognitive aspects of Alzheimer's disease, dementia, and aphasia. Alzheimer's Disease therapeutics and modeling of progression for clinical prognostication, validation of biological markers, and enhancing design of AD clinical trials.

Publications

Collapse All | Expand All

Poster Presentations

View Details | Collapse All | Expand All

  • Benge J, Balsis S, Geraci L, Massman P, Doody R. How well does the ADAS-cog measure the spectrum of Alzheimer's disease severity? An item response theory analysis. Neurology. 2009;72(11 Suppl 3):A247.
  • Doody R, Chan W, Pavlik V, Massman P, Darby E, Rountree S, Szigeti K. Age at onset and pre- morbid IQ influence early progression rates in AD. Neurology. 2009;72(11 Suppl 3):A478.
  • Cummings J, Doody RS, Gavrilova S, Sano M, Aisen P, Seely L, Hung D. Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia. 2008;4(4 Suppl):T770-1.
  • Doody RS, Ferris SH, Salloway S, Meuser TM, Murthy AK, Li MC, Goldman R. Interrater reliability between expert and nonexpert physicians in the assessment of amnestic MCI in the community setting. Alzheimer's & Dementia. 2008;4(4 Suppl):T263.
  • Doody RS, Gavrilova S, Thomas R, Aisen P, Bachurin S, Seely L, Hung D. Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study. Alzheimer's & Dementia. 2008;4(4 Suppl):T771.
  • Murthy AK, Schuff N, Suhy J, Doody RS, Goldman R. The effects of donepezil on Alzheimer's disease progression monitored by MRI. Alzheimer's & Dementia. 2008;4(4 Suppl):T55.
  • Rountree S, Pavlik V, Chan W, Doody RS. Persistent antidementia drug treatment and survival in an Alzheimer's disease (AD) cohort. Alzheimer's & Dementia. 2008;4(4 Suppl):T698-9.
  • Sparks L, Kivipelto M, Doody RS, Waters D, Jones RW, Feldman H, Pickering E, Hu X, Hall S, Breazna A, DeMicco DA, Hey-Hadavi J, Schindler RJ. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Effect of atorvastatin on Alzheimer's disease progression by APOE4 genotype. 2008 International Conference on Alzheimer's Disease (ICAD), Chicago, Illinois (July 26-31, 2008).
  • Doody RS, Ferris S, Salloway S, Meuser T, Murthy A, Li MC, Goldman R. Inter-rater reliability between expert and nonexpert physicians in the diagnosis of amnestic MCI in the community setting. Neurology. 2008;70(11 Suppl 1):A147.
  • Doody RS, Gavrilova S, Aisen P, Hirmand M, Sano M. Dimebon improves patient function and decreases caregiver assistance time in Alzheimer's disease: One-year clinical trial results. Neurology. 2008;70(11 Suppl 1):A98.
  • Ferris S, Doody R, Gavrilova S, Sano M, Aisen P, Seely L. Dimebon improves memory, orientation, language, and praxis in patients with mild to moderate Alzheimer's disease: Results of a one-year placebo-controlled study. Neurology. 2008;70(11 Suppl 1):A393-4.
  • Pavlik VN, Doody RS, Rountree SD, Darby EJ. Vitamin E use is associated with improved survival in an AD cohort. Neurology. 2008;70(11 Suppl 1):A146.
  • Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Gulley A, Doody RS. Exposure to anti-dementia drugs slows clinical progression of Alzheimer's disease (AD). Ann Neurol. 2007;62 Suppl 11:S55.
  • Doody R, Garrilova S, Sano M, Thomas R, Aisen P, Bachurin S, Seely L, Hung D. Results of a one-year randomized, placebo-controlled trial of dimebon for the treatment of mild to moderate Alzheimer's disease. Alzheimer's & Dementia. 2007;3(3 Suppl):S199-200.
  • Jones R, Doody R, Sparks DL, Feldman H, Kivipelto M, Breazna A, Sovei M, DeMicco D, Hey-Hadavi J. Lipitor's effect in Alzheimer's dementia (LEADe) study: Baseline characteristics. Alzheimer's & Dementia. 2007;3(3 Suppl):S192-3.
  • Rountree SD, Pavlik VN, Chan W, Darby EJ, Doody RS. Clinical factors associated with the preprogression rate (PPR) in Alzheimer's disease (AD). Alzheimer's & Dementia. 2007;3(3 Suppl):S130.
  • Senanarong V, Hamphadungkit K, Poungvarin N, Cummings J, Doody R. The dementia and disability in Thai elderly project: Prevalence of mild cognitive impairment with one-year follow-up and the prevalence of dementia in community-dwelling Thai elderly. Alzheimer's & Dementia. 2007;3(3 Suppl):S178.
  • Doody R, Gavrilova S, Sano M, Thomas R, Aisen P, Seely L, Hung D. Dimebon improves cognition, function, and behavior in patients with mild- moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled study. Neurology. 2007;68(12 Suppl 1):A353.
  • Feldman H, Sparks L, Doody R, Kivipelto M, Jones R, Sovel M, Breazna A, Hey-Hadavi J. Design and baseline data for a study of Lipitor's effect in Alzheimer's disease (LEADe). Neurodegener Dis. 2007;4 Suppl 1:333.
  • Doody R, Pavlik V, Massman P, Rountree S, Waring S, Darby E, Chan W. Predicting progression and survival in Alzheimer's disease. Alzheimer's & Dementia. 2006;2(3 Suppl):S83.
  • Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS. Is functional decline necessary for a diagnosis of Alzheimer's disease? Alzheimer's & Dementia. 2006;2(3 Suppl):S263.
  • Rountree SD, Waring SC, Chan W, Darby EJ, Doody RS. Clinically presenting mild cognitive impairment (MCI): Variable presentations and their outcomes. Alzheimer's & Dementia. 2006;2(3 Suppl):S269.
  • Waring SC, Paranilam JM, Doody RS, Darby EJ, Massman PJ, Chan W. Preprogression rate, cardiovascular comorbidity, and survival in Alzheimer's disease. Alzheimer's & Dementia. 2006;2(3 Suppl):S159.
  • Doody R, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression of Alzheimer's disease. Neurology. 2006;66(5 Suppl 2):A347.
  • Acharya D, Massman P, Doody R. Neuropsychological and demographic correlates of apraxia in a large cohort of Alzheimer's patients. Int J Neurosci. 2006;12 Supple S1:47.
  • Benge J, Massman P, Jenkins R, Thornton G, Doody R. Phonemic cued performance on the Boston Naming Test: Longitudinal change and its correlates in Alzheimer's disease. Int J Neurosci. 2006;12 Supple S1:55.
  • Jenkins R, Massman P, Benge J, Thornton G, Doody R. Naming improvement with phonemic cues: Which Alzheimer's patients benefit most? Int J Neurosci. 2006;12 Supple S1:51.
  • Thornton G, Massman P, Benge J, Jenkins R, Doody R. Category-letter fluency discrepancies in healthy older adults: Normative data and reliability. Int J Neurosci. 2006;12 Supple S1:192.
  • Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM. Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease. Ann Neurol. 2005;58 Suppl 9:S49-50.
  • Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM. Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease. Alzheimer's & Dementia. 2005;1(1 Suppl):S67.
  • Thal LJ, Thomas RG, Grundman M, Bennett DA, Doody RS, Ferris SH, Galasko DR, Jin S, Levey AI, Petersen RC. Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis. Alzheimer's & Dementia. 2005;1(1 Suppl):S93.
  • Issa A, Rountree S, Waring S, Yeh S, Doody RS. Mild cognitive impairment types and their outcomes. Neurology. 2005;64(6 Suppl 1):A168.
  • Massman P, Doody RS. ADAS-Cog change rates in MMSE Strata relevant to clinical trials. Neurology. 2005;64(6 Suppl 1):A70.
  • Pavlik V, Doody RS, Massman P, Chan W, Yeh S. Relationship of premorbid IQ and education to progression of Alzheimer's disease. Neurology. 2005;64(6 Suppl 1):A317.
  • Schindler R, Corey-Bloom J, Doody R, Zhang R, Leni JR, Li H. Donepezil is safe and well-tolerated in AD patients at doses of up to 20 mg/day. European Journal of Neurology. 2004;11(Suppl 2):44.
  • Wirth Y, Doody RS, Schmitt FA, Mobius HJ, Stoffler A. Functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. European Journal of Neurology. 2004;11(Suppl 2):193.
  • Doody R, Pratt R, Posner H, Kumar D. Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits. Neurobiol Aging. 2004:25 Suppl 2:S469-70.
  • Massman P, Doody R. Longitudinal analysis of the Alzheimer's Disease assessment scale in a large cohort of probable AD patients. Neurobiol Aging. 2004;25 Suppl 2:S120.
  • Tariot P, Doody R, Peskind E, Winblad B, Reisberg B, Stoffler A, Graham S, McDonald S. Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary. Neurobiol Aging. 2004;25 Suppl 2:S99-100.
  • Wirth Y, Doody RS, Schmitt FA, Mobius HJ. Functional benefits of memantine treatment for patients with moderate to severe Alzhemier's disease. Neurobiol Aging. 2004;25 Suppl 2:S205.
  • Wirth Y, Doody R, Schmitt F, Mobius HJ, Stoffler A. Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease. Int J Neuropsychopharmacol. 2004;7 Suppl 2:S207.
  • Doody RS, Pratt RD, Perdomo CA, the Donepezil 307 and 308 vaD Study Groups. Donepezil-treated patients demonstrate global benefits on the Clinician's Interview-Based Impression of Change-Plus version: A comparison of Alzheimer's disease versus vascular dementia. Neurology. 2003;60(5 Suppl 1):A412.
  • Ferris SH, Schmitt FA, Doody RS, Moebius H-J, Stoeffler A, Reisberg BJ. Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease. Neurology. 2003;60(5 Suppl 1):A414.
  • Clark C, Eubank D, Peskind E, Galasko D, Morris J, McKeel D, Farlow M, Weitlauf S, Quinn J, Kaye J, Knopman D, Arai H, Doody R, Decarli C, Leight S, Lee V, Xie S, Trojanowski J. How well do cerebral spinal fluid tau levels discriminate autopsy confirmed Alzheimer's disease from other dementia diagnoses? Neurobiol Aging. 2002;23(1 Suppl):S274.
  • Doody RS. Pathogenesis and treatment strategies for selected therapies under development. Neurobiol Aging. 2002;23(1 Suppl):S144.
  • Reisberg B, Mobius H, Stoffler A, Schmitt F, Doody R, Ferris S. Long term treatment with the NMDA antagonist memantine: results of a 24-week, open label extension study in moderately severe to severe Alzheimer's disease. Neurobiol Aging. 2002;23(1 Suppl):S555.
  • Waring S, Doody RS. Survival in patients with dementia from a large multi ethnic population. Neuroepidemiology. 2002;21:211.
  • Doody RS, Kershaw P. The cognitive benefits of galantamine are sustained for at least 24 months: Results of a longterm extension trial in Alzheimer's disease. Neurology. 2001;56(8 Suppl 3):A456.
  • Waring S, Doody RS. Racial differences among patients with Alzheimer's disease from a large multi ethnic population. Neuroepidemiology. 2001;20:118.
  • Doody RS. Cholinesterase inhibitors: Benefits and limitations. Neurobiol Aging. 2000;21(1 Suppl):S8.
  • Mohs R, Doody R, Morris J, Ieni J, Perdomo C, Pratt R. Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1-year placebo-controlled functional survival study. Neurology. 2000;54(Suppl 3):A415.
  • Sumaira R, Doody R, Lai EC. Profoundly advanced Alzheimer's disease: Patient characteristics, functional status, disease progression, and care burden. Neurology. 2000;54(Suppl 3):A417.
  • Doody R, Geldmacher DS, Pratt RD, Perdoma CA. Uninterrupted long-term donepezil treatment results in optimal efficacy with retained safety. Consult Pharm. 1999;14(10):1142.
  • Mohs R, Doody R, Morris J, Ieni J, Rogers S, Perdomo C, Pratt R. Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year placebo-controlled attrition study. Eur Neuropsychopharmacol. 1999;9 Suppl 5:S328.
  • Doody RS, Geldmacher DS, Pratt RD, Perdomo CA. Optimal donepezil efficacy in Alzheimer's disease is dependent on continued administration. J Neurol. 1999;246 Suppl 1:I52.
  • Azher S, Doody RS, Haykal H, Dunn JK, Liao T-Y. Does ApoE4 correlate with MRI changes in Alzheimer's disease? Neurology. 1999;52(Suppl 2):A366.
  • Doody RS, Pratt R, Perdomo C. Clinical benefits of donepezil: Results from a long-term phase III extension trial. Neurology. 1999;52(Suppl 2):A174.
  • Petit H, Doody RS, Pratt R. Donepezil improves cognition and global function in Alzheimer's disease: Results from U.S. and multinational phase III clinical trials. Eur Neuropsychopharmacol. 1998;8 Suppl 2:S274.
  • Doody RS, Clark C, Farlow M, Foster N, Gonzales N, Liao J, Lai E, Massman P. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease patients. Neurobiol Aging. 1998;19(Suppl 45):S303.
  • Kataki M, Doody RS, Liao J, Sims J. The presence of APO E4 does not influence rate of decline in Alzheimer's disease. Neurobiol Aging. 1998;19(Suppl 45):S137.
  • Doody RS. Current therapeutic standards in the treatment of Alzheimer's disease. Proceedings of the Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. 1998:32.
  • Rogers S, Mohs R, Friedhoff L, Doody RS. Research outcome measures in Alzheimer's disease: Statistical significance, effect size and responder analysis - How do they translate to clinical relevance? Proceedings of the Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. 1998:32.
  • Quinn JF, Benson DF, Clark C, Doody RS, Jagust W, Knopman D, Kaye J. Outcome measures in dementia trials-video CIBIC validity and reliability. Neurology. 1997;48(3):A233-A234.
  • Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil HCI (E2020) improves cognitive and global function in patients with mild and moderately severe Alzheimer's disease: Results of a 15-week phase III study. American College of Neuropsychopharmacology (ACNP), 35th Annual Meeting in San Juan, Puerto Rico (Dec. 9-13, 1996).
  • Kashani A, Doody RS, Wayner MJ, Phelix CF. Prevalence of uncontrolled hypertension in a population of Alzheimer's patients. International Behavioral Neuroscience Society (ISBN), 5th Annual Meeting in Cancun, Mexico (May 2-5, 1996).
  • Grundman M, Petersen R, Morris J, Ferris S, Sano M, Farlow M, Doody RS, Galasko D, Ernesto C, Thomas R, Thal L, the ADCS Cooperative Study. Rate of dementia of the Alzheimer's type (DAT) in subjects with mild cognitive impairment. Neurology. 1996;46(2):A403.
  • Rogers S, Doody RS, Mohs R, Friedhoff L. E-2020 Produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): Results of a 30-week phase III trial. Neurology. 1996;46(2):A217.
  • Sabbagh N, Smith RG, Lynn P, Doody RS, Appel SH, Killian JH. Pharmacologic evidence for autonomic psudomotor dysfunction in patients with Alzheimer's disease. Neurology. 1996;46(2):A162.
  • Olin J, Clark C, Doody RS, Schmitt F, Ferris S, Morris J, Reisberg B, Sneider L. Reliability and validity of a new clinical global rating scale for Alzheimer's clinical trials. Int J Neurosci. 1996;2:4.
  • Olin J, Schneider L, Clark C, Doody RS, Ferris S, Morris J, Reisberg B, Schmitt F. A new clinical global rating scale for Alzheimer's clinical trials. Gerontologist. 1995;35(2):63.
  • Doody RS, Young R, Lynn P, Cooke N, Rosenfield JE. Estrogen and psychomotor performance. J Neuropsychiatry Clin Neurosci. 1995;7(3):410.
  • Doody RS, Lynn P, Massman PJ. A calculated measure to predict rate of progression in Alzheimer's disease. Neurology. 1995;45(4 Suppl 4):A195.
  • Massman PJ, Doody RS. Sex differences involving naming in Alzheimer's disease: Stronger relationships with left hemisphere functioning in men. Int J Neurosci. 1995:145.
  • Doody RS, Massman PJ, Nance ML. Psychometric profiles of Alzheimer's disease (AD) with/without white matter changes compared to subcortical ischemic vascular dementia (IVD). Neurology. 1994;44(4 Suppl 2):A196.
  • Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs. Neurology. 1994;44(4 Suppl 2):A194.
  • Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease. Int J Neurosci. 1994:43.
  • Doody RS, Massman P. Dysfluency in the speech of AD patients. Ann Neurol. 1993;34(2):249.
  • Doody RS, Welsh K. Literacy and cognition in northern Thailand. Ann Neurol. 1993;34(2):249.
  • Dunn W, Doody RS, Gopnik M, Ashizawa T. Simulation analysis of a large British pedigree segregating a newly characterized autosomal dominant language disorder: Familial developmental dysphasia. Am J Hum Genet. 1993;53(Suppl):A1692.
  • Kotrla K, Chacko R, Jhingran S, Doody RS. Neuroimaging findings and clinical variables associated with psychosis in Alzheimer's disease. American Psychiatric Association (APA), 146th Annual Meeting in San Francisco, California (May 22-27, 1993).
  • Massman P, Doody RS. Correlates of asymmetric motor speed in Alzheimer's disease. J Clin Exp Neuropsychol. 1993;15:31.
  • Massman P, Doody RS. Neuropsychological correlates of apraxia in Alzheimer's disease patients. Arch Clin Neuropsychol. 1992;8:249-50.
  • Doody RS. Positioning: Neurology and anthropology enabling practices. American Anthropological Association (AAA), 90th Annual Meeting in Chicago, Illinois (Nov. 20-24, 1991).
  • Doody RS, Strittmatter WJ, Jhingran S. Single photon emission computerized tomography (SPECT) in Alzheimer's disease and multiple-infarct dementia. Ann Neurol. 1991;30(2):249-50.
  • Feher E, Mahurin R, Doody RS, Cooke N, Simms J, Pirozzolo F. Establishing the limits of the mini-mental state: MMS "subtests" versus a full neuropsychological battery. Ann Neurol. 1991;30(2):285-6.
  • Mahurin R, Feher E, Doody RS, Inbody S. Positive and negative psychiatric symptoms in Alzheimer's disease. Ann Neurol. 1991;30(2):239.
  • Doody RS, Jankovic J. The alien hand and related signs. Neurology. 1991;41(3 Suppl 1).
  • Doody RS. Sense and nonsense: Dissemination and empiricism in practice. American Anthropological Association (AAA), 89th Annual Meeting in New Orleans, Louisiana (Nov. 27 - Dec. 2, 1990).
  • Doody RS, Hrachovy RA. Recurrent posterior-type aphasia associated with a seizure focus. Electroencephalogr Clin Neurophysiol. 1991;79:28.
  • Feher E, Doody RS, Whitehead J, Priozzolo F. Progressive nonfluent aphasia. Neurology. 1990;40(4 Suppl 1).
  • Ornish DM, Scherwitz LW, Doody RS, et al. Effects of stress management and dietary changes in treating ischemic heart disease. American College of Cardiology (ACC), 31st Annual Scientific Session in Atlanta, Georgia (April 25-29, 1982).

Invited Speaker and Participant in Courses,

Collapse All | Expand All


Workshops, Symposia and Conferences

  • Key note speaker: Update on Alzheimer's Disease. Annual ADMDC/Alzheimer's Association Houston and SE Texas Chapter Community Program, Houston Museum of Natural Science/IMAX Theater, Houston, Texas. (Aug. 28, 2008)
  • Symposium chair: Alzheimer's Disease Therapeutics. International Conference on Alzheimer's Disease, Chicago, Ill. (July 30, 2008)
  • Invited speaker: Cholinesterase Inhibitors and Memantine: What are the Best Practices. Alzheimer's Disease Summit, Washington DC. (May 3, 2008)
  • Panelist: Research and Exploration. Rice Alumni Leaders, Rice University, Houston, Texas. (April 26, 2008)
  • LEADe Steering Committee: Late Breaking News Report: Lipitor's Effect in Alzheimer's Disease. American Academy of Neurology, Chicago, Ill. (April 16, 2008)
  • Invited speaker: Treatment in Alzheimer's Disease. Texas Public Health Association Conference, San Antonio, Texas. (March 7, 2008)
  • Chair: Clinical Relevance and Treatment Update in Mild Cognitive Impairment. International Hong Kong/Springfield Pan-Asia Symposium on Advances in Alzheimer's Disease Therapy. (Feb. 29, 2008)
  • Invited speaker: Latest Update on Alzheimer's Disease. Singapore General Hospital/Tan Tock Seng Hospital, Singapore. (Feb. 26, 2008)
  • Invited speaker: Progression of Alzheimer's Disease. Baylor Neurology Grand Rounds, Houston, Texas. (Feb. 22, 2008)
  • Invited speaker: Alzheimer's Disease Therapeutics. Schering-Plough, Kenilworth, N.J. (Feb. 8, 2008)
  • Invited speaker: Aspects of Memory. Sciencia Society, Rice University, Houston, Texas. (Jan. 15, 2008)
  • Invited speaker: Update on Alzheimer's Disease. ADMDC/Alzheimer's Association Annual Community Update, Houston, Texas. (Sept. 6, 2007)
  • Invited speaker: The Development of Alzheimer's Disease Therapies from the Laboratory to Practice. 2007 Texas Conference on Alzheimer's Disease and Care, Austin, Texas. (Aug. 23, 2007)
  • Co-Chair: Emerging Compounds. Alzheimer's Association International Conference on Prevention of Alzheimer's Disease, Washington, DC. (June 12, 2007)
  • Invited speaker: Update on Alzheimer's Disease. Baylor College of Medicine Neurology Grand Rounds, Houston, Texas. (Jan. 29, 2007)
  • Invited speaker: What is Really Known about Prevention and Treatment of Alzheimer's Disease. ADMDC/Alzheimer's Association Annual Community Update, Houston, Texas. (Aug. 31, 2006)
  • Co-Chair: 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain. (July 19, 2006)
  • Co-Chair: Neurologic Highlights: Dementia and Behavioral Neurology. American Academy of Neurology, San Diego, Calif. (April 6, 2006)
  • Invited speaker: Treating Alzheimer's Disease from a Specialist's Perspective. Central Texas Health Care System, Waco, Texas. (March 9, 2006)
  • Invited speaker: Alzheimer's Disease and Mild Cognitive Impairment. Texas Neurological Society, Austin, Texas. (Feb. 24, 2006)
  • Invited speaker: Update on Alzheimer's Disease. ADMDC/Alzheimer's Association Annual Community Update, Houston, Texas. (Sept. 19, 2005)
  • Co-Chair: Dementia and Aging. American Academy of Neurology, Miami, Fla. (April 13, 2005)
  • Invited speaker: Prevention and Treatment of Alzheimer's Disease. Baylor Methodist Neurology Grand Rounds, Houston, Texas. (March 21, 2005)
  • Invited speaker: Prevention and Treatment of Alzheimer's Disease. American Association of Clinical Psychiatrists, Houston, Texas. (March 18, 2005)
  • Invited speaker: Prevention and Treatment of Alzheimer's Disease. Texas Neurological Society, Austin, Texas. (Feb. 11, 2005)

Contact Information

Rachelle S. Doody, M.D., Ph.D.
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-7416
Fax: 713-798-5326
Email: